Diabetic Macular Edema
Conditions
Interventions
Experimental Group:Anti-VEGF combined with micropulse laser therapy (anti-VEGF as above, laser performed within 1 week after the first injection)
Control Group:Anti-VEGF monotherapy (Conbercept, 3 PRN regimen)
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older, diagnosed with type 2 diabetes; 2. Center-involved DME, OCT showing CMT = 300 µm; 3. HbA1c = 9% (to control blood sugar interference); 4. Best corrected visual acuity ETDRS letters 20-78 (equivalent to Snellen 20/400-20/32); 5. For patients with both eyes affected, only the first affected eye is included.
Exclusion criteria
Exclusion criteria: 1. History of previous vitrectomy 2. Systemic use of glucocorticoids or other intraocular injections or laser treatments within 3 months 3. Presence of other ocular comorbidities affecting macular function 4. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA;CMT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Microperimetry;Number of hyperreflective foci (HRF) in the outer retina;Aqueous Humor Factor ;Adverse event;OCTA Vessel Density ;Ellipsoid Zone Integrity Score; | — |
Countries
China
Contacts
Public ContactBincui Cai
Tianjin Medical University Eye Hospital
Outcome results
None listed